Document is current

Any future updates will be listed below

Olverembatinib (HQP1351): a third-generation tyrosine kinase inhibitor in the treatment of hematologic and solid malignancies—a comprehensive review of clinical outcomes

Crossref DOI link: https://doi.org/10.1007/s12672-026-04438-x

Published Online: 2026-01-17

Update policy: https://doi.org/10.1007/springer_crossmark_policy

About CrossMark